Evaluating Treatment Options of EGFR Inhibitors
Dr. Garon explains the factors guiding his choice between EGFR inhibitors for EGFR+ NSCLC and when he might consider alternatives like afatinib or erlotinib.
EP: 1.Robert’s Journey With EGFR+ Metastatic NSCLC
EP: 2.The Impact of Molecular Testing on Treatment Choices for NSCLC
EP: 3.Overview of FLAURA and MARIPOSA-2 Clinical Trials
EP: 4.Clinical Experience of Amivantamab in EGFR+ NSCLC Patients
EP: 5.Factors in Selecting Treatment Options for EGFR+ NSCLC
EP: 6.Evaluating Treatment Options of EGFR Inhibitors
EP: 7.Considerations for Second-Line Treatment Decisions in EGFR+ NSCLC: Sequencing Strategies and First-Line Choices
EP: 8.Jason’s Journey with ALK+ Metatstatic NSCLC
EP: 9.Barriers and Challenges in Biomarker Testing for ALK+ NSCLC
EP: 10.Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC
EP: 11.Overview of Current Treatment Landscape of ALK Inhibitors
EP: 12.Clinical Experience of Lorlatinib ALK+ NSCLC Patients
EP: 13.Patient Factors Considered when Choosing Treatment Selection
EP: 14.Treatment Strategies in Disease Progression in ALK+ NSCLC
EP: 15.Evaluating ALK Inhibitors in Treatment Sequencing and Testing
EP: 16.Future Therapies for ALK+ Metastatic NSCLC
Video content above is prompted by the following:
- What factors guide your choice, and in which cases might you consider alternatives like afatinib or erlotinib?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
